The Anatomy of a Healthtech Strategy

Clinical Problem & Evidence Strategy

Solving a Problem That Clinicians, Payers, and Patients All Agree Matters

In healthtech, you do not get to define the problem — the clinical evidence does. Unlike consumer software where user engagement can substitute for rigorous validation, healthcare requires proof that your product actually improves clinical outcomes, reduces costs, or meaningfully enhances care delivery. The evidence strategy must be designed before the product is built because clinical validation timelines, study design, and endpoint selection fundamentally shape what you build and how you build it. Livongo's entire product strategy was built around generating clinical evidence that technology-enabled diabetes management reduced HbA1c levels and emergency room visits — because those endpoints determined whether payers would reimburse the product. Pear Therapeutics obtained FDA authorization for the first prescription digital therapeutic by designing clinical trials that met the same evidence standards as pharmaceutical drugs.

• →Identify a clinical problem where the evidence gap between standard care and your intervention is measurable and meaningful to payers
• →Design your evidence strategy before your product strategy: what clinical endpoints will you measure, what study design will you use, and how long will validation take
• →Invest in peer-reviewed publications — health system decision-makers and payers require published evidence, not marketing claims
• →Build relationships with clinical key opinion leaders (KOLs) who can validate your approach and serve as champions within health systems

Regulatory Pathway Design

Navigating FDA, HIPAA, and the Compliance Labyrinth

Healthcare regulation is simultaneously the biggest barrier and the biggest moat in healthtech. The FDA, HIPAA, state medical boards, and payer regulations create a compliance labyrinth that takes years and millions of dollars to navigate. But for companies that successfully navigate it, regulation becomes an almost impenetrable competitive moat — because every competitor must cross the same multi-year, multi-million-dollar barrier. The regulatory strategy must be chosen carefully: some products can be marketed as general wellness tools without FDA oversight. Others require FDA 510(k) clearance (typically 6–12 months). Software classified as a medical device may require De Novo authorization (12–24 months) or PMA approval (2–5 years). The choice of regulatory pathway directly impacts product design, clinical evidence requirements, go-to-market timeline, and capital requirements.

• →Determine your regulatory classification early: general wellness, clinical decision support, 510(k) medical device, De Novo, or PMA — each has dramatically different timelines and requirements
• →Build HIPAA compliance and security architecture into the technical foundation — retrofitting HIPAA compliance is extremely expensive and often requires complete rearchitecting
• →Engage with the FDA proactively through pre-submission meetings to align on classification and evidence requirements before investing in clinical trials
• →Use regulatory clearance as a competitive moat: once obtained, it creates a 12–36 month head start over competitors who must complete the same process

Stakeholder Alignment & Value Proposition

Satisfying Patients, Providers, Payers, and Administrators Simultaneously

Healthcare is the only major industry where the user (patient), the prescriber (provider), the payer (insurer), and the administrator (health system executive) are all different entities with different — and often conflicting — incentives. A patient wants the best possible care regardless of cost. A provider wants clinical effectiveness and minimal workflow disruption. A payer wants cost reduction and outcome improvement. A health system administrator wants operational efficiency and regulatory compliance. The most common healthtech failure is building a product that delights one stakeholder while ignoring the others. Hundreds of patient-facing apps have failed because they were not integrated into clinical workflows. Dozens of provider tools have failed because payers would not reimburse them. The winning strategy aligns all four stakeholders around a shared value proposition.

• →Map the incentives, pain points, and decision-making processes of all four stakeholders before designing your go-to-market strategy
• →Build a value proposition that translates into different languages for each stakeholder: clinical outcomes for providers, cost savings for payers, experience improvement for patients, and operational efficiency for administrators
• →Identify the economic buyer and the clinical champion separately — they are rarely the same person, and both must be convinced for adoption to succeed
• →Design clinical workflow integration that adds less than 2 minutes per patient encounter — anything more will face provider resistance regardless of clinical benefit

Reimbursement & Business Model Design

Building a Business Model That the Healthcare Economy Will Actually Fund

Healthcare reimbursement is the single most misunderstood aspect of healthtech strategy. In most industries, if a customer wants a product and can afford it, they buy it. In healthcare, a patient may want a product, a provider may prescribe it, and the patient may be willing to pay — but if the payer does not reimburse it, the transaction often does not happen. The reimbursement landscape includes fee-for-service (payment per procedure or visit), value-based care (payment tied to outcomes), employer-sponsored benefits (sold to HR departments as wellness or benefits programs), and direct-to-consumer (patients pay out of pocket). Each model has different sales cycles, revenue profiles, and scaling characteristics. Livongo achieved rapid scale by selling to self-insured employers — bypassing the slow payer negotiation process entirely. Teladoc secured CPT codes for virtual visits, enabling fee-for-service reimbursement through existing insurance infrastructure. The business model choice should be driven by the fastest path to meaningful revenue, not the theoretically optimal reimbursement model.

• →Choose your initial reimbursement pathway based on speed to revenue, not theoretical market size: employer-sponsored benefits close in months; payer contracts take 12–24 months; fee-for-service requires CPT code coverage
• →Design product pricing around healthcare budget categories: clinical operations, pharmacy benefits, wellness programs, or risk adjustment — each has different budget owners and approval processes
• →Build ROI models that quantify the financial impact in terms payers understand: per-member-per-month cost savings, emergency room visit reduction, hospital readmission prevention
• →Layer reimbursement pathways over time: start with employer-sponsored or cash pay, then add payer contracts and fee-for-service reimbursement as evidence accumulates

Distribution & Health System Integration

Getting Your Product Into the Hands of Patients and Providers

Healthcare distribution is the strategic challenge that kills more healthtech companies than any other. The healthcare system is extraordinarily fragmented: there are over 6,000 hospitals, 200,000 physician practices, 900 health insurance plans, and 160 million employer-covered lives in the United States alone. Reaching even 1% of this market requires navigating procurement committees, IT security reviews, EHR integration requirements, clinical workflow adoption, and privacy compliance — and each health system has its own process. The most successful healthtech distribution strategies fall into three categories: direct enterprise sales to health systems (high revenue per account but long sales cycles), platform distribution through EHR marketplaces and health plan partnerships (lower cost per acquisition but less control), and consumer-pull strategies that create patient demand that health systems cannot ignore.

• →Build EHR integration capability early — health systems will not adopt products that do not integrate with Epic, Cerner, or their existing clinical systems
• →Pursue lighthouse accounts: one or two prestigious health system deployments create credibility that accelerates the entire sales pipeline
• →Invest in implementation and customer success teams that understand clinical workflow — healthtech deployment is not software deployment; it requires clinical change management
• →Leverage payer and employer channels for distribution in addition to direct health system sales — selling through the entity that pays often has shorter sales cycles than selling to the entity that delivers care

Clinical Workflow Integration & Provider Adoption

Making Technology Invisible Inside the Care Delivery Process

Provider adoption is the graveyard of healthtech products. Physicians and nurses operate under extreme time pressure, see dozens of patients per day, and have been burned by decades of poorly designed technology that promised to help but instead added documentation burden and clicks. The average physician already spends 2 hours on EHR documentation for every 1 hour of patient care. Any product that adds to this burden — even by 30 seconds per encounter — will face resistance from the people whose adoption is essential for clinical and commercial success. The most successfully adopted healthtech products share a common design principle: they are invisible inside the existing workflow. They do not require new logins, new screens, or new steps. They surface the right information at the right moment within the tools providers already use. Epic's app marketplace succeeds because apps launch within the Epic interface. Clinical decision support tools that surface alerts within the EHR note are adopted; those that require switching to a separate application are ignored.

• →Design for the clinical workflow as it actually exists, not as you wish it existed — shadow providers for at least 40 hours before finalizing product design
• →Minimize provider burden: the product should save time on net, not add time. If your product adds any steps, it must demonstrably remove more steps elsewhere
• →Integrate within existing tools (EHR, clinical communication platforms) rather than requiring providers to use a standalone application
• →Measure adoption through clinical utilization metrics (orders placed, alerts actioned, recommendations followed), not login counts or page views

“

The best healthtech products are the ones clinicians forget are there. They surface the right information at the right moment without requiring the clinician to do anything different. The moment you ask a doctor to change their workflow, you have already lost.

— Bob Kocher, MD, General Partner at Venrock

Scaling & Outcome Measurement

Proving Value at Population Scale While Maintaining Clinical Integrity

Scaling in healthtech is fundamentally different from scaling in software. In SaaS, scaling means acquiring more users and expanding revenue. In healthtech, scaling means demonstrating that clinical outcomes improve as the product reaches more patients, providers, and health systems — and that the economic value created justifies the cost at population scale. This requires sophisticated outcome measurement infrastructure: the ability to track clinical endpoints (disease progression, hospitalization rates, medication adherence), economic endpoints (total cost of care, ER utilization, readmission rates), and experience endpoints (patient satisfaction, provider satisfaction, workflow efficiency) across large, diverse populations. The companies that scale successfully in healthtech — Teladoc, Livongo, and Athenahealth — all invested heavily in outcome measurement as a core product capability, not a reporting afterthought.

• →Build outcome measurement infrastructure into the product from day one — the ability to demonstrate value at scale is your most important scaling asset
• →Track clinical, economic, and experience outcomes simultaneously: payers care about cost, providers care about outcomes, patients care about experience, and you need all three
• →Publish outcomes data regularly: annual outcome reports, peer-reviewed publications, and case studies create a compounding evidence base that accelerates sales
• →Invest in health equity measurement: demonstrate that your product delivers equitable outcomes across demographic groups — health systems and payers increasingly require this data